Biocept Inc (NASDAQ:BIOC) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,957,896 shares, an increase of 101.1% from the January 15th total of 973,539 shares. Approximately 49.5% of the company’s stock are short sold. Based on an average daily trading volume, of 6,952,855 shares, the days-to-cover ratio is currently 0.3 days.
Biocept stock opened at $1.04 on Thursday. The company has a market cap of $2.43 million, a PE ratio of -0.04 and a beta of 3.09. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.63 and a quick ratio of 2.50. Biocept has a 52 week low of $0.66 and a 52 week high of $12.30.
Biocept (NASDAQ:BIOC) last released its earnings results on Tuesday, November 13th. The medical research company reported ($2.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.71). The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $1.02 million. Biocept had a negative net margin of 715.42% and a negative return on equity of 456.20%. As a group, analysts forecast that Biocept will post -9.17 earnings per share for the current year.
BIOC has been the subject of several research analyst reports. Zacks Investment Research cut Biocept from a “hold” rating to a “sell” rating in a research note on Tuesday, November 27th. ValuEngine cut Biocept from a “buy” rating to a “hold” rating in a research note on Thursday, November 15th.
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Further Reading: Blue-Chip Stocks
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.